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We describe 2 spatially distinct foci of human African trypansomiasis in eastern Uganda. The Tororo and Soroti
foci ofTrypanosomabrucei rhodesiense infection were genetically distinct as characterized by 6 microsatellite and
1 minisatellite polymorphic markers and were characterized by differences in disease progression and host-
immune response. In particular, infections with the Tororo genotype exhibited an increased frequency of pro-
gression to and severity of the meningoencephalitic stage and higher plasma interferon (IFN)– concentration,
compared with those with the Soroti genotype. We propose that the magnitude of the systemic IFN- response
determines the time at which infected individuals develop central nervous system infection and that this is con-
sistent with the recently described role of IFN- in facilitating blood-brain barrier transmigration of trypano-
somes in an experimental model of infection. The identification of trypanosome isolates with differing disease
progression phenotypes provides the first field-based genetic evidence for virulence variants in T. brucei
rhodesiense.
Human African trypanosomiasis (HAT) is caused by in-
fection with the tsetse fly–transmitted hemoflagellates
Trypanosoma brucei rhodesiense (in East and southern
Africa) and T. brucei gambiense (in West and Central
Africa). This disease is reemergent, with a current esti-
mate of300,000 cases and a further 60 million people
at risk of infection [1]. The early (or hemolymphatic)
stage ofHAT commences 1–3weeks after an infective fly
bite with parasites proliferating within the blood and
lymphatic system. Symptoms include general malaise,
anemia, headache, pyrexia, weight loss, and weakness.
The late (meningoencephalitic) stage of infection coin-
cides with the invasion of the central nervous system
(CNS) by parasites and is associated with psychiatric,
motor, sensory, and sleep disorders, eventually pro-
gressing to a final stage involving seizures, somnolence,
coma, and death [2]. Typically T. brucei rhodesiense in-
fections are acute, whereas T. brucei gambiense infec-
tions present as a chronic disease [3]. However, within
each subspecies, there are differences in the rate of dis-
ease progression. In T. brucei rhodesiense infection,
large-scale spatial differences in disease presentation
have been described, in which “severe” and “mild” dis-
ease are associated with “northern” and “southern” dis-
ease foci, respectively [4] and inwhich themild disease is
associated with lower levels of systemic inflammatory
response [5]. These differences in disease severity may
result from variation in host resistance, genetic variation
in parasite virulence, socioeconomic and environmental
factors, or a combination of all.
Progression to the late stage requires penetration of
the blood-brain barrier by trypanosomes. Recent animal
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model studies have demonstrated that interferon (IFN)– plays
a critical role in this process bymodulating endothelial basement
membrane laminin expression and lymphocyte transmigration
[6]. Both clinical and experimental animal studies have observed
systemically high levels of IFN- during trypanosome infection
[7–9], and after trypanosome invasion of the CNS there is a
direct relationship between the severity of neuropathology and
expression of IFN- in the brain [10].
Here, we describe 2 spatially distinct HAT foci in eastern
Uganda with genetically distinct parasites, allowing us to test the
hypothesis that disease progression is determined by parasite
genotype and host IFN- response.
SUBJECTS, MATERIALS, AND METHODS
Study sites and subjects. Patients with HAT and noninfected
control individuals presenting to local hospitals or identified
during community surveillance were recruited in eastern
Uganda in 2002 and 2003. The Tororo, Iganga, Jinja, and Busia
Districts define a common ecotope for the transmission of T.
brucei rhodesiense by Glossina fuscipes fuscipes, which will be re-
ferred to henceforth as the Tororo focus, whereas the Soroti Dis-
trict contains a separate G. fuscipes fuscipes ecotope, where HAT
emerged as a new epidemic in 1998-1999 [11]. Diagnosis was by
microscopic detection of trypanosomes in wet blood films, in
Giemsa-stained thick blood films, or in the buffy coat fraction
after microhematocrit centrifugation [12]. After admission, a
detailed physical examination was performed, and neurological
involvement was assessed using the Glasgow Coma Score (GCS)
[13]. The GCS gives a measure of the degree of impairment of
consciousness, with a score of 15 as normal. The ranges 14–12,
11–8, 8 indicate mild, moderate, and severe impairment of
consciousness, respectively. A clinical history was taken either
from the patient or the attendant relative, and patients were clas-
sified on the basis of language to either Bantu, Western Nilo
Saharan, or Eastern Nilo Saharan ethnic groups [14]. Stage was
determined by examination of cerebrospinal fluid (CSF), using
the World Health Organization criteria in which patients with
trypanosomes in the CSF and/or a cell count5 cells/mm3 were
classified as being in the late stage [15]. Early stage infection was
treated with suramin and late-stage infection with melarsoprol
[9]. Subjects or their guardians signed consent forms after re-
ceiving standard information in their local language. Protocols
were approved by the Grampian Research Ethics Committee
(Aberdeen) and the Ministry of Health (Uganda). Individuals
with malarial parasitemia and microfilaremia were excluded
from the study.
Blood samples obtained before treatment commenced were
collected into EDTA Vacutainers (Greiner) and centrifuged for
10 min at 3000 g. Platelet-depleted plasma was aliquoted and
frozen immediately in liquid nitrogen. CSF samples obtained as
part of normal-stage diagnosis were also frozen and stored in
liquid nitrogen. Trypanosome DNA from a subset of case pa-
tients was sampled by applying a 200-L suspension taken from
the buffy coat layer to FTA cards (Whatman Bioscience), which
were dried and stored at room temperature. Case patients were
selected to include representatives from each village and no
more than one case per compound/family.
Cytokine assays. IFN-, interleukin (IL)–1, IL-6, trans-
forming growth factor (TGF)–, and IL-10 concentrations were
measured using a solid-phase sandwich ELISA (OptiEIA; BD
Pharmingen), as described elsewhere [16]. Biological limits of
detection for these assayswere 1.8, 10.2, 8.3, 19.2, and 1.6 pg/mL,
respectively.
FTA filter preparations and whole-genome amplification.
Discs of 1.2 mm in diameter were cut out of each blood spot by
use of a HarrisMicro Punch (Whatman). The discs were washed
3 timeswith 200L of FTApurification reagent (Whatman) and
twice with 200L of 1mmol/L Tris-EDTA buffer (pH 8.0), with
incubation for 5 min at each wash. The washed discs were air-
dried for 1 h and then used as substrate for whole-genome am-
plification reactions.
Whole-genome amplification was done using multiple dis-
placement amplification (MDA) technology directly on washed
FTA punched discs [17]. Three independent reactions were
done for each sample, and products were stored at20°C.
Polymerase chain reaction (PCR)–based genotyping. One
microliter of each MDA product was used as template for PCR,
in a volume of 20 L. The microsatellite loci (ch1/18, ch2/5,
ch2/PLC, ch3/5L5, ch4/M12C12, and ch5/JS2) and minisatellite
locus (ch3/292) used in this study have been described elsewhere
[18, 19]. Both outside and nested PCR primers for each marker
are detailed in table 1.
PCR conditions were as follows: PCR buffer (45mmol/L Tris-
HCl [pH 8.8], 11 mmol/L [NH4]2SO4, 4.5 mmol/L MgCl2, 6.7
mmol/L 2-mercaptoethanol, 4.4 mol/L EDTA, 113 g·mL-1
bovine serum albumin, and 1 mmol/L each of 4 deoxyribonu-
cleotide triphosphates), 1 mol/L of each oligonucleotide
primer, and 1U ofTaq polymerase (Abgene) per 20-L reaction
(2.5 U per 50 L reaction). For the nested reactions, 1 L of a
1:100 dilution of first-round product was used as template in the
second-round PCR. PCR products were resolved by electropho-
resis on a 3%Nusieve GTG agarose gel (Cambrex), stained with
ethidium bromide, and visualized under UV light.
Allele size determination. The number and size of alleles
amplified in each sample was determined using 1 fluorescently
labeled primer for each locus (FAM), followed by separation of
products using a capillary-based sequencer (ABI 3100; Applied
Biosystems). DNA fragment size was determined relative to a set
of ROX-labeled size standards (GS500 markers; Applied Biosys-
tems) using GeneScan software, which allowed resolution to the
level of 1 bp.
For the minisatellite locus (ch3/292), allele band sizes were
determined on the basis ofmobilities relative to a reference stan-
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dard lane (restriction fragments of  HindIII and 174
HaeIII), as described elsewhere [20].
Genetic analysis. The programs Clustering Calculator [21]
and Treeview (version 1.6.6) [22] were used to generate a den-
drogram in which multilocus genotypes were compared using
unweighted arithmetic average as the clustering method and a
pairwise distance matrix of the multilocus genotypes (Jaccard’s
similarity coefficient) for the input data. This allowed the anal-
ysis of the similarity between each multilocus genotype to be
determined. The genetic data analysis (GDA) program [23] was
used to determine Nei’s genetic distance (D) [24] and Wright’s
fixation index (FST) [25] between each group of isolates from
different foci.
Statistical analyses. The statistical package JMP5 (SAS In-
stitute) was used. The distributions of cytokine concentrations
were all right skewed. After log transformation, all approached
normality. Log-transformed cytokine values were compared us-
ing appropriate parametric tests as indicated in Results, using
the linear modeling platform in JMP. Distributional assump-
tions were tested using Shapiro-Wilks test and Levene’s test for
homogeneity of variance. Age was stratified as follows: 0–5,
6–14, 15–29, and 30 years. Categorical variables were com-
pared using Pearson’s 2 or Fisher’s exact test.
RESULTS
Disease in Tororo and Soroti Districts caused by distinct
genetic variants. One hundred forty-four patients with HAT
were recruited during the period January 2002 to August 2003,
of whom115 came from the Soroti focus and 29 from theTororo
focus. Parasite DNA from a subset of 22 subjects in the Tororo
focus and 27 subjects in the Soroti focus was subject to whole-
genome amplification followed by genotyping with 6 microsat-
ellites and 1minisatellitemarker, by nested PCR. Themultilocus
genotype of each sample was determined based on the combina-
tion of alleles at the 7 loci, revealing 30 distinct multilocus geno-
types. To determine the relationship between the isolates, a den-
drogram based on Jaccard’s similarity index was constructed
(figure 1). A T. brucei rhodesiense sample, isolated from a patient
with sleeping sickness in Malawi in 2002 (NKK/T/02-02) [5],
was also included in this analysis for comparison. Two distinct
clusters of genotypes (groups 1 and 2 in figure 1) were identified
using this approach, and the bootstrap value for the node that
separates the 2 groups is high (97 of 100 replications). Group 1
genotypes contain only isolates from Soroti, whereas group 2
genotypes contain only isolates from Tororo, clearly demon-
strating that there are distinct parasite genotypes that are re-
sponsible for sleeping sickness in the 2 individual foci. This was
confirmed by measurement of Nei’s genetic distance between
the groups (0.143) and by Wright’s fixation index (0.071).
Disease characteristics of subjects with HAT in Tororo and
Soroti. The disease characteristics at each focus are summa-
rized in table 2. Although there were no significant differences in
parasitemia and anemia between the 2 foci, a significantly higher
proportion of patients had progressed to the late stage in the
Tororo focus at the time of diagnosis. There was a higher fre-
quency of hepatomegaly and splenomegaly and also a small but
significant increase in body temperature observed in patients
fromTororo, who also exhibited a significantly higher frequency
of moderate (GCS of 9–11) or severe (GCS of 8 or less) impair-
ment of consciousness. As this result could be influenced by the
higher proportion of late-stage patients in Tororo, the frequency
of moderate or severe impairment of consciousness was also
compared for late-stage cases only. Again, a significantly higher
frequency of patients with a GCS of 12 was found in Tororo
Table 1. Microsatellite outside and nested polymerase chain reaction primer sequences.
Locus
Outside Nested
Primer Sequence (5'33') Primer Sequence (5'33')
ch1/18 1/18-C tataatgcgtttgtgagaat 1/18-A-FAM tgtgagaatggtactcacgcgctg
1/18-D gaagggagggaacagaagcaggg 1/18-B caacgttagcacacaattcctgtg
ch2/5 2/5-C tatcgcggttatgtggatttgtgg 2/5-AFAM atggcgtgtatcacattcgtgatg
2/5-D cacaacaaaactgccatgaggtac 2/5-B ccgttggcattaggcacaagta
ch2/PLC PLC-G2 ttaagtggacgacgaaataacaaca 2/PLC-GFAM caacgacgttggaagagtgtgaac
PLC-H4 ttcaaacaccgtccccctcaataat 2/PLC-H3 ccactgacctttcatttgatcgctttc
ch3/5L5/2 5L5/2-AA gagcgtacattgcaggtagtgcgtagcg 3/5L5/2-AFAM gtacgtggttaaccacaacctact
5L5/2-C acgaagaaacgaagcaaagaag 2/5L5/2-B ggaaactgcttaaacttgcgtgag
ch3/292 3/292-G1 cggaaaacgagggtgtgttacgcgac 3/292-G gctgaacctgtgggcccctcaattg
3/292-H gctgaacctgtgggcccctcaattg 3/292-H2 acaccccctctccacttcagatac
ch4/M12C12 M12C12-C aaaacctcatccagtcgcactgg M12C12-AFAM tggacacacagaagcctaccg
M12C12-B taccctcatcaagtggtcg M12C12-D agtgtggtggtgcgtgcaaacttgg
ch5/JS2 JS2-C agtaatgggaatgagcgtcaccag JS2-AFAM gattggcgcaacaactttcacatacg
JS2-D gatcttcgcttacacaagcggtac JS2-B ctttcttccttggccattgttttactat
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than in Soroti. Despite the apparently more advanced disease
presentation in the Tororo focus, there was no significant differ-
ence in the duration of illness as reported by patients. Therewere
differences in age and sex composition in Tororo and Soroti;
however, these factors were not significantly (P  .3) associated
with infection stage.
Characterization of Tororo and Soroti foci by differences in
plasma IFN- and IL-6 concentrations. The plasma concen-
trations of a panel of cytokines involved in the inflammatory
response and its regulation were then measured (figure 2). The
concentrations of IFN- in Tororo and of IL-6, IL-10, IL1-,
and TGF- in both Soroti and Tororo were elevated in relation
to control levels in patients with HAT, and furthermore there
were significant differences in the concentrations of IFN-
(P  .0001, unpaired t test) and IL-6 (P  .05) between the 2
foci. TNF-	 concentration was not significantly increased in ei-
ther patient group. Because blood samples from a subset of
Tororo and Soroti patients had been used for parasite genotyp-
ing (figure 1), a further analysis was carried out in which the
plasma cytokine levels of only genotyped infections were mea-
sured. The results from this analysiswere entirely consistentwith
those from the full Tororo and Soroti study cohorts (table 3). For
comparison, the relevant plasma cytokine data for Malawi pa-
tients published inMacLean et al. [5] is also presented in table 3.
Because the Tororo and Soroti groups differed in age and sex
structure (table 2), these factors were tested for effects on IFN-
and IL-6 concentrations. Although age had no significance as an
explanatory variable, female patients from Soroti showed a sig-
nificant increase in plasma IFN- concentration (for female pa-
tients with HAT, geometric mean [95% confidence interval
{CI}] concentration of 78.2 (60.9–102.5) pg/mL; for male pa-
tients with HAT, geometric mean [95% CI] concentration of
Figure 1. Dendrogram generated by an unweighted arithmetic average as the clustering method, showing the similarities between trypanosome
multilocus genotypes. Bootstrap values based on 100 replicates are shown for the main nodes. Groups 1 and 2 comprise the Tororo and Soroti genotypes,
respectively.
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41.7 (30.8–56.2) pg/mL; P  .05, unpaired t test). No similar
sex difference was evident in the Tororo patients. Because of the
apparent effect of sex on IFN- levels in Soroti, cytokine data
were reanalyzed using age- and sex-matched pairs of case pa-
tients. Each of the 29 Tororo patients was paired with a Soroti
patient of the same sex andwithin 5 years of the same age.Where
1 patient met these criteria, the pair with the closest diagnosis
datewas selected. In this subset ofmatched cases, IFN- and IL-6
concentrations continued to differ between the groups (for
Tororo, geometricmean [95%CI] IFN- concentration of 262.4
(179.5–383.7) pg/mL; for Soroti, geometric mean [95% CI]
IFN- concentration of 68.0 [48.9–94.6] pg/mL; P  .001,
paired t test) (for Tororo, geometric mean [95% CI] IL-6 con-
centration of 76.7 [47.5–123.9] pg/mL; for Soroti, geometric
mean [95% CI] IL-6 concentration of 27.9 [16.3–44.7] pg/mL;
P  .01, paired t test).
Independence of IFN- response from subject ethnicity.
Analysis of plasma IFN- levels in the aggregated Tororo and
Soroti patient groups suggested that ethnolinguistic group was a
significant determinant of response (F2,137 
 12.6; P  .0001),
with the lowest concentrations in Eastern Nilo Saharan patients
(table 4). However 99% of the Soroti subjects (table 2) were of
Eastern Nilo Saharan background, and thus the apparent influ-
ence of ethnicity on IFN- could be confounded by the predom-
inance of this one ethnic group. This interpretation is supported
by the observation that, when only patients from the Tororo
focus (n 
 29) were analyzed, ethnicity had no effect on plasma
IFN- concentration (table 4).
As a further test for the effects of ethnicity on IFN- concen-
tration, the 6 Eastern Nilo Saharan subjects from the Tororo
focus were age and sex matched with 6 Eastern Nilo Saharan
subjects from Soroti. In this subset of case patients, there con-
tinued to be a significant difference in plasma IFN- concentra-
tion between the groups (for Soroti, geometric mean [95% CI]
of 60.3 [27.1–134.2] pg/mL; for Tororo, geometric mean [95%
CI] of 365.0 [221.4–544.6] pg/mL; P  .05, paired t test).
Plasma IL-6 concentration did not vary according to subject eth-
nicity.
Association of CNS IFN- concentration with moderate
and severe coma. Patients with trypanosomiasis from Tororo
and Soroti did not exhibit any significant difference in CSF
IFN- concentration (table 5). Because there was an increased
frequency of patients with moderate (GCS of 12) and severe
impairment of consciousness (GCS of 8) in Tororo, the rela-
tionship between CSF IFN- concentration and GCS was inves-
tigated. Although there was no significant effect of GCS on CSF
IFN- in Soroti, in Tororo, patients with moderate (n 
 5) and
severe (n 
 3) impairment of consciousness exhibited a signif-
icantly higher concentration of IFN- in CSF (table 5) than pa-
tients with a GCS of 12–14 (mild impairment of consciousness,
n 
 6) and 15 (normal, n 
 15).
DISCUSSION
HAT caused by T. brucei rhodesiense presents a spectrum of clin-
ical profiles, from acute infection rapidly progressing to the le-
thal meningoencephalitic stage to more chronic infections that,
Table 2. Characteristics of patients with sleeping sickness recruited in Tororo and Soroti Districts.
Characteristic
All patients with HAT
(n  144)
Soroti patients
(n  115)
Tororo patients
(n  29)
Age, median (range), years 22 (2–85) 20 (2–85) 25 (15–39)
Female 56 58.6 44.8
Packed cell volume, mean  SE, % 29.70.5 29.50.6 30.70.9
Temperature, median (IQR), °C 36.8 (36.4–37.2) 36.8 (36.4–37.0) 37.4 (36.8–38.0)a
Late stage (meningoencephalitic) 75.7 72.4 93.5b
GCS 12
All cases 13.3 6.9 37.9c
Meningoencephalitic cases only 17.1 9.7 40.7c
Parasitemia, median (IQR)d 0.5 (0–3) 0.4 (0–1) 1.5 (0–16.5)
Reported duration of illness, median (IQR), days 56 (22–86) 47 (21–67) 62 (30–102)
Lymphadenopathy 41 43.1 33.3
Hepatomegaly 4.1 1.0 14.8b
Splenomegaly 15.2 10.4 31.0b
Ethnic composition, Bantu; Eastern Nilo Saharan;
Western Nilo Saharan 6.9; 83.3; 9.8 0.8; 99.2; 0 31; 20.7; 48.3
NOTE. Data are percentage of patients, unless otherwise specified. GCS, Glasgow Coma Score; HAT, human African trypanoso-
miasis; IQR, interquartile range.
a Significantly increased over Soroti (P  .001, unpaired t test).
b Significantly higher frequency in Tororo (P  .001, 2 test).
c Significantly higher frequency in Tororo (P  .05, Fisher’s exact test).
d Parasites per 10 fields (at 400) of wet film.
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similar to T. brucei gambiense infection, take several months or
more to progress to CNS infection [4]. It has been proposed that
such differences in disease tempo may be controlled by either
parasite genotype or host genotype or by a combination of both
[5]. Spatial genetic variation of parasite populations certainly
does occur [26], but its relationship to pathology has hitherto
been unclear.
In 1998, the first cases of a new epidemic of sleeping sickness
emerged in Soroti District [11], some 150 km north of the his-
toric Tororo focus, and between 2002 and 2003 we conducted a
cross-sectional survey of cases in both foci. Analysis of clinical
histories indicated a difference in disease virulence between the 2
foci, with Tororo subjects showing increased progression to the
CNS infection stage. Although this could have been the result of
a longer period of illness before admission, patient interview
data indicated no significant difference in duration of disease
between Tororo and Soroti. This suggests that the more ad-
vanced progression in Tororo is not simply the result of a longer
duration of disease. The difference in clinical profile between
these spatially distinct disease foci allowed us to test the hypoth-
Figure 2. Plasma concentrations of interferon (IFN)– (A), interleukin (IL)–10 (B), IL-1 (C), IL-6 (D), and transforming growth factor (TGF)– (E) in
patients (gray boxes) and control subjects (white boxes) in the Tororo and Soroti foci. Boxes show the median and 25th and 75th percentiles; whiskers
show 10th and 90th percentiles. Dots represent outliers. *Significantly increased over control (P  .0001, unpaired t test on log-transformed data).
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esis that disease progression—and thus virulence—in sleeping
sickness is determined by parasite genotype. On the basis of the
difference in allele type andmultilocus genotype, we have shown
that the geographically separated T. brucei populations in Soroti
and Tororo, isolated at the same time and from the same host
type, are genetically distinct, providing evidence of a lack of gene
flow between these populations. This conclusion was supported
by a moderate genetic distance between the populations. Thus,
we demonstrate for the first time that distinct parasite genotypes
circulate in spatially separated foci and are associated with dif-
ferences in virulence as measured by progression to and severity
of the CNS infection stage.
It has previously been demonstrated in experimental HAT
models that pathology is associated with the systemic [27] and
CNS production [10] of inflammatory cytokines. We therefore
investigated the relationship between systemic cytokine re-
sponse and difference in clinical presentation between patients
in Tororo and Soroti. There was a generalized up-regulation of
plasma IL-1, TGF-, and IL-10 in all patients, consistent with
the finding of previous studies of T. brucei rhodesiense [16] and
T. brucei gambiense [28, 29]. However, IFN- and IL-6 were
detected at consistently different concentrations in the plasma of
Tororo subjects compared with Soroti subjects, after controlling
for differences in age, sex, and ethnicity between the 2 foci.
IFN- concentration was higher in Tororo patients, whereas
IL-6 concentration was higher in Soroti patients. Studies in the
mouse model of infection have demonstrated that IFN- plays a
pivotal role in the host response to trypanosomiasis. It is de-
tected in splenic T cells within 24 h of infection [30], reaches
higher plasma concentrations with laboratory trypanosome
strains of increasing virulence [7], and appears to be derived
from both the innate cellular immune system [31] and adaptive
responses by T cells to variant surface glycoprotein epitopes
[32], trypanin [33], and other undefined parasite antigens.
IFN- contributes to pathogenesis through macrophage activa-
tion and resulting nitric oxide and TNF-	 production [27, 34,
35]. However, IFN- appears to be essential for the control of
parasitemia in mouse models [36–38]. For the present study, of
particular relevance is the recent finding in the mouse model
that IFN- is a regulator of the blood-brain barrier, which try-
panosomesmust cross to initiate CNS infection [6]. Mice genet-
ically manipulated to be deficient for IFN- and the IFN- re-
ceptor all showed impaired and delayed invasion of the brain
parenchyma, with an accumulation of parasites between the en-
dothelial and parenchymal basement membranes. If these find-
ings also apply to human disease, individuals responding with
high levels of IFN- would be expected to show increased pro-
gression toCNS infection, and this is the case in the Tororo focus
in this study. Patients with HAT in Tororo also showed a higher
frequency of moderate and severe impairment of consciousness
(as measured by GCS), compared with those in Soroti. Inmouse
models, up-regulation of IFN- production in the brain paren-
Table 3. Plasma cytokine concentration (geometric mean [95% confidence in-
terval]) in patients with human African trypanosomiasis (HAT) with genotyped
parasite infections.
Cytokine
Soroti (genotype 1)
(n  27)
Tororo (genotype 2)
(n  22)
Malawi HAT cases
reported in [5]
IFN-, pg/mLa 74.4 (48.9–114.4) 254.6 (156.0–411.6) 56.8 (34.1–93.7)
IL-6, pg/mLb 79.8 (58.5–108.9) 51.9 (37.7–68.7) 121.5 (73.7–200.3)
IL-10, pg/mLa 115.6 (83.9–159.2) 130.3 (90.9–186.8) 134.3 (90.0–194.4)
IL-1, pg/mLa 76.7 (54.6–107.8) 79.8 (58.5–108.9) 82.2 (50.9–132.9)
TGF-, ng/mLc 1.58 (0.86–2.92) 2.51 (1.28–4.91) 6.0 (2.7–13.8)
NOTE. IFN, interferon; IL, interleukin; TGF, transforming growth factor.
a Tororo was significantly increased over Soroti and previously reported Malawi [5] values
(P  .001, unpaired t test).
b Soroti was significantly increased over Tororo (P  .05, unpaired t test); Malawi was signif-
icantly increased over Soroti and Tororo (P  .05, Tukey post-hoc test).
c Soroti and Tororo were significantly lower than previously reported Malawi value (P  .001).
Table 4. Plasma interferon (IFN)– levels and patient ethnicity.
Ethnicity All patients Tororo patients only
Bantu 183.0 (92.2–365.0) [n  10] 242.0 (121.5–483.2) [n  9]
Western Nilo Saharan 288.6 (148.4–555.6) [n  14] 288.6 (148.4–555.6) [n  14]
Eastern Nilo Saharan 64.1 (52.4–78.3) [n  120]a 270.4 (119.1–620.2) [n  6]
NOTE. Data are geometric mean (95% confidence interval) IFN- levels, in picograms per milliliter.
a Significantly reduced compared with Western Nilo Saharan and Bantu (P  .05).
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chyma is associated with the onset and increasing severity of
neuroinflammation [10, 39], leading to the neurological se-
quelae of sleeping sickness.When the level of IFN- in theCSFof
patients was investigated, it was found that, in Tororo, patients
with sleeping sickness with a GCS of12 exhibited significantly
higher levels of CSF IFN-. Thus, we provide the first clinical
evidence of an involvement of IFN- in the initiation and sever-
ity of meningoencephalitic sleeping sickness.
The significance of the higher concentration of plasma IL-6 in
Soroti patients is not clear. IL-6 is a multifunctional cytokine
with proinflammatory characteristics but also acts as a neuro-
protective factor [40]. Although IL-6 has previously been shown
to be expressed at high levels both in the peripheral circulation
and in the CNS during experimental mouse [10, 41] and human
[16] trypanosomiasis, the functional relationship between IL-6
and the pathogenesis of HAT requires further investigation.
Plasma IL-10, IL-1, and TGF- were elevated at similar lev-
els in both Tororo and Soroti. In a previous study contrasting
mild and severe HAT inMalawi andUganda, respectively, it was
proposed that higher levels of plasma TGF- observed in mild
cases may point to a role of this cytokine in regulating inflam-
matory pathology [5]. In the present study, TGF- was not re-
lated to disease severity. However, when compared with the cy-
tokine responses reported in MacLean et al. [5], plasma TGF-
levels in both Tororo and Soroti patients were lower than those
in patients with HAT in Malawi, while at the same time plasma
IFN- levels in Tororo patients were significantly higher than
those in Malawi patients, which were not significantly different
from the plasma IFN- concentrations in Soroti patients. Thus,
while the variations in disease severity we describe within
Uganda appear to be related to differences in the IFN- response
to infection, at larger spatial scales—such as those encompassing
the mild and severe HAT symptoms of the southern and north-
ern areas of East Africa, respectively—additional involvement of
inflammatory pathology and its regulation by TGF- may be
involved.
Field clinical studies of HAT are limited to cross-sectional
design by ethical and logistical constraints; therefore, it is not
possible to confirm causality or mechanism in the relationship
between plasma and CSF cytokines and disease progression. The
detailed dissection of the host response to the Tororo and Soroti
parasite genotypes and the mechanistic role played by IFN- in
promoting CNS invasion and neuropathology now requires
study in refined experimental mouse models [10] in which the
invasion of the CNS and the progression of CNS pathology may
be measured.
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